Henning von Oertzen PARTNER ▪ More than 26+ years experience in mid cap transactions and international investments ▪ 20+ years entrepreneurial and CEO experience ▪ Built up the deal sourcing and origination for Riverside in Europe ▪ Formerly Chairman of the Frankfurt Rhine Main entrepreneurs/company owners association of Small and Medium-sized businesses Daniel Mahnert-Lueg PARTNER ▪ More than 19+ years professional experience in Industry, Private Equity and Consulting between US, China and Germany ▪ Formerly in Sales at Pfizer Nutrition (sold to Nestlé), responsible for product launches in China ▪ Associate in Hong Kong for AEA Investors (3.5 bn USD under management) ▪ MBA from CEIBS in Shanghai and BS from Stern Business School of NYU ▪ Speaks fluent Chinese André Cerbe DIRECTOR ▪ More than 16+ years professional experience in Industry, Private Equity, and Mezzanine funding ▪ 5 years of Managing Director experience in medical technologies ▪ Extensive experience in corporate finance, investment management and financial restructuring Lui Kam DIRECTOR - CHINA OFFICE ▪ More than 21+ years of professional experience in China and France ▪ Previously Partner at a cross boarder M&A boutique in China ▪ Worked as Managing Director China of a Western Metal Processing company with 900 Employees worldwide  ▪ Started his career as an Engineer working for the French Ministry of Defence Moritz Grosse ANALYST ▪ Experience in Audit & Tax Consulting ▪ Experience in small and mid-cap transactions as well as venture capital fundraising CONTACT USIMPRINTLINKEDIN

News SALE OF SOMATEX Westlake Partners is glad to announce the sale of its portfolio company SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, to Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health. Westlake Partners acquired SOMATEX in 2014 and since then, has successfully internationalized, innovated, professionalized and grown the company by an active management approach. The acquisition of SOMATEX supports Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care. “During the investment period, we reached some key milestones with SOMATEX: We developed a clear strategic focus, optimized organizational structures and processes, we launched several innovative products and expanded the global footprint of SOMATEX with sales offices in the U.S. and China.” said André Cerbe, Investment Director of Westlake Partners and former Managing Director of SOMATEX. Westlake Partners is a circle of international entrepreneurs and investors with extensive experience building companies. Following an entrepreneurial and collaborative approach, Westlake seeks active investments into small and medium-sized companies by providing both growth capital as well as strategic and operational support transforming them into global leaders in their niche. LEARN MORE CONTACT USIMPRINTLINKEDIN